The mTOR inhibitors, including AZD8055, ABI‐009, CC‐223, Rapamycin, and RAD001, have been widely investigated in clinical trials and effectively applied in immunotherapy or adjuvant therapy across various cancers [251, 252] (see Table 1). The gene discussed is MTOR; the disease is cancer.